Long-term remission after erlotinib therapy in an elderly patient with advanced non-small-cell lung cancer. Case report and conclusions for clinical practice

Renata Duchnowska, Anna Siemiątkowska, Bartłomiej Grala, Marta Smoter


Small molecule tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) - gefitinib and erlotinib - have
recently been used as a therapeutic option in advanced non-small cell lung cancer (NSCLC) patients relapsing after first- or
second-line chemotherapy. We report here a case of long-term remission in an elderly, non-smoking woman with advanced
NSCLC after chemotherapy failure, who was selected for erlotinib therapy using demographic and clinical criteria. Based on
this example and on the literature data we discuss the need for careful patient selection for this new therapeutic method.


non-small cell lung cancer; erlotinib; targeted therapies
Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl